The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study
Open accessAbstract
Purpose To evaluate factors associated with visual field (VF) progression, using all available follow-up through nine years after treatment initiation, in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Design Longitudinal follow-up of participants enrolled in a randomized clinical trial. Participants 607 newly diagnosed glaucoma patients. Methods In a randomized clinical trial, 607 subjects with newly diagnosed open-angle glaucoma were initially treated with either medication or trabeculectomy. After treatment initiation and early follow-up, subjects were evaluated clinically at 6-month intervals. Study participants in both arms of the CIGTS were treated aggressively in an effort to reduce intraocular pressure (IOP) to a level at or below a predetermined, eye-specific target pressure. VF progression was analyzed using repeated measures models. Main outcome measures VF progression, measured by Humphrey 24-2 full threshold testing and assessed by the change in the mean deviation (MD), and an indicator of substantial worsening of the VF (MD decrease of ≥3 dB from baseline), assessed at each follow-up visit. Results Follow-up indicates minimal change from baseline in each initial treatment group’s average MD. However, at the eight year follow-up examination, substantial worsening (≥3 dB) of MD from baseline was found in 21.3% and 25.5% of the initial surgery and initial medicine groups, respectively. The effect of initial treatment on subsequent VF loss was modified by time (P<0.0001), baseline MD (P=0.03), and diabetes (P=0.01). Initial surgery led to less VF progression than initial medicine in subjects with advanced VF loss at baseline, whereas subjects with diabetes had more VF loss over time if treated initially with surgery. Conclusions The CIGTS intervention protocol led to a lowering of IOP that persisted over time in both treatment groups. Progression in VF loss was seen in a subset increasing to over 20% of the subjects. Our findings regarding initial surgery being beneficial for subjects who present at diagnosis with more advanced VF loss, but detrimental for patients with diabetes, are noteworthy and warrant independent confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Factors for Glaucoma Progression and the Effect of Treatment: The Early Manifest Glaucoma Trial
Leske, M. C. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.48 · Cited by 2,030
Predictors of Long-term Progression in the Early Manifest Glaucoma Trial
Leske, M. C., Heijl, A., Hyman, L., Bengtsson, B., Dong, L., & Yang, Z. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.016 · Cited by 1,363
Lichter, P. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00873-9 · Cited by 1,178
Self-citationRisk factors for progression of visual field abnormalities in normal-tension glaucoma
Drance, S., Anderson, D. R., & Schulzer, M. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00964-3 · Cited by 790
Nouri-Mahdavi, K., Hoffman, D., Coleman, A. L., Liu, G., Li, G., Gaasterland, D., & Caprioli, J. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.02.017 · Cited by 704
Musch, D. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90147-1 · Cited by 402
Self-citationMigdal, C., Gregory, W., & Hitchings, R. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31120-1 · Cited by 373
Cited by
Jonas, J. B., Aung, T., Bourne, R. R., Bron, A. M., Ritch, R., & Panda-Jonas, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31469-1 · Cited by 1,322
Glaucoma in Adults—Screening, Diagnosis, and Management: A Review
Stein, J. D., Khawaja, A. P., & Weizer, J. S. (2021) · JAMA · doi:10.1001/jama.2020.21899 · Cited by 728
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
Garway-Heath, D. F., Crabb, D. P., Bunce, C., Lascaratos, G., Amalfitano, F., Anand, N., Azuara-Blanco, A., Bourne, R. R., Broadway, D. C., Cunliffe, I. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62111-5 · Cited by 660
Weinreb, R. N., Leung, C. K. S., Crowston, J. G., Medeiros, F. A., Friedman, D. S., Wiggs, J. L., & Martin, K. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.67 · Cited by 632
Jayaram, H., Kolko, M., Friedman, D. S., & Gazzard, G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01289-8 · Cited by 592
Metadata
- Authors
- Musch, D. C., Gillespie, B. W., Lichter, P. R., Niziol, L. M., & Janz, N. K.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 116
- Issue
- 2
- Pages
- 200-207.e1
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W1768004330
- Cited by
- 439
- References
- 15
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study. https://app.cochat.ai/papers/10.1016/j.ophtha.2008.08.051
- The paper
- Musch, D. C., Gillespie, B. W., Lichter, P. R., Niziol, L. M., & Janz, N. K. (2009). Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. https://doi.org/10.1016/j.ophtha.2008.08.051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.